Biotech5 years ago
Theranexus successfully completes Phase 2 Trial for THN102 in Parkinson’s disease
The biopharmaceutical company Theranexus has just completed the Phase 2 trial of its THN102 drug candidate in Parkinson's disease. The study demonstrated the efficacy of THN102...